ACADIA Pharmaceuticals Inc (ACAD)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 3.73 | 1.28 | 1.03 | 1.02 | 1.16 | 1.26 | 1.49 | 1.46 | 1.53 | 1.76 | 2.35 | 2.48 | 2.43 | 1.53 | 1.85 | 1.97 | 2.12 | 2.58 | 3.30 | 3.16 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 1.76 | 2.09 | 2.28 | 2.36 | 2.01 | 2.18 | 1.81 | 1.87 | 1.35 | 1.26 | 1.24 | 1.17 | 0.93 | 0.86 | 0.84 | 0.81 | 0.72 | 0.66 | 0.61 | 0.59 |
ACADIA Pharmaceuticals Inc's inventory turnover ratio has shown fluctuating trends over the past few years, ranging from a high of 3.73 in December 2024 to a low of 1.02 in March 2024. This indicates that the company's ability to sell its inventory efficiently has varied significantly during this period.
On the other hand, the receivables turnover ratio and payables turnover ratio have not been provided in the data, suggesting that it may not be relevant or applicable for analysis in the context of ACADIA Pharmaceuticals Inc.
Looking at the working capital turnover ratio, there is a consistent increasing trend from 0.59 in March 2020 to 1.76 in December 2024. This demonstrates an improvement in the company's efficiency in generating revenue relative to its working capital over the years.
Overall, the analysis of ACADIA Pharmaceuticals Inc's activity ratios indicates both fluctuations and improvements in different aspects of its operational efficiency and financial performance during the period under review.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 97.89 | 285.90 | 354.26 | 359.27 | 313.98 | 289.76 | 245.53 | 250.44 | 238.26 | 206.81 | 155.41 | 147.04 | 150.28 | 239.14 | 196.84 | 185.69 | 171.97 | 141.49 | 110.72 | 115.35 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on the data provided for ACADIA Pharmaceuticals Inc, let's analyze the activity ratios:
1. Days of Inventory on Hand (DOH):
- The Days of Inventory on Hand measures how many days, on average, the company holds inventory before selling it.
- The trend for DOH is fluctuating over the periods mentioned, ranging from a low of 97.89 days to a high of 359.27 days.
- A high DOH value like 359.27 days as of March 31, 2024, indicates that the company is taking longer to sell its inventory, which could lead to excess inventory or potential obsolescence.
2. Days of Sales Outstanding (DSO):
- Unfortunately, there is no data provided for Days of Sales Outstanding, making it challenging to assess the efficiency of the company in collecting receivables.
- DSO would have provided insight into how quickly the company collects revenues from its credit sales.
3. Number of Days of Payables:
- Similar to DSO, there is no data provided for the Number of Days of Payables, making it difficult to analyze how efficient the company is in paying its suppliers.
- This ratio would have indicated how long the company takes to pay its suppliers, impacting its cash flow and relationships with vendors.
In conclusion, while the Days of Inventory on Hand shows fluctuating trends for ACADIA Pharmaceuticals Inc, the lack of data for Days of Sales Outstanding and Number of Days of Payables limits a comprehensive assessment of the company's overall efficiency in managing its working capital and operating cycle.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | — | — | 11.36 | — | 92.98 | 8.40 | 78.57 | 7.95 | 65.47 | 7.30 | 55.28 | 6.57 | 6.29 | 48.22 | 49.73 | 58.78 | 71.96 |
| Total asset turnover | 0.81 | 0.95 | 0.97 | 0.95 | 0.97 | 1.00 | 0.86 | 0.79 | 0.88 | 0.85 | 0.84 | 0.79 | 0.69 | 0.66 | 0.64 | 0.61 | 0.56 | 0.53 | 0.52 | 0.49 |
Based on the provided data, ACADIA Pharmaceuticals Inc's long-term activity ratios can provide insights into how efficiently the company is utilizing its fixed and total assets to generate revenue.
1. Fixed Asset Turnover: This ratio measures the efficiency of the company in generating revenue from its fixed assets. The trend of ACADIA's fixed asset turnover ratio shows a fluctuating pattern over the years. It started at a high level in March 2020, with a sharp decline in March 2021, followed by a fluctuating pattern with occasional peaks and troughs. The ratio reached its highest point in March 2023 at 92.98, indicating that the company generated $92.98 in revenue for every dollar invested in fixed assets. However, it is worth noting that data is missing for some periods, which may impact the trend analysis.
2. Total Asset Turnover: This ratio assesses how effectively the company uses its total assets to generate revenue. The total asset turnover ratio for ACADIA Pharmaceuticals Inc has generally shown an increasing trend from March 2020 to December 2022, indicating improved efficiency in generating revenue from its total assets during this period. There was a peak in September 2023 at 1.00, showing that the company generated $1 in revenue for every dollar of assets held. However, there was a slight decline in the ratio towards the end of the period, dropping to 0.81 by December 2024.
Overall, analyzing these long-term activity ratios provides valuable insights into ACADIA Pharmaceuticals Inc's operational efficiency and asset utilization, highlighting areas of strength and potential improvement in the company's business operations.